Stock listing

BOATS:JBIO Jade Biosciences, Inc. Stock

US listing (BOATS) of Jade Biosciences, Inc. · home listing NASDAQ:JBIO

Follow Jade Biosciences, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:JBIO

$15.31 USD -0.18 (-1.2%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:JBIO

Past year +33.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$15.00 – $15.53 USDNov 20, 2026
Volume
1.02M sharesNov 20, 2026
Market cap
$1.06B USDAt the close on Nov 20, 2026 · price × 69.19M shares outstanding
52-week range
$11.02 – $28.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$14.75M USDMedian day 829,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Jade Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:JBIO · Home$15.31 USD-0.18 (-1.2%)1,021,412$15.00$15.53$15.00$15.49Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:JBIO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$15.31-0.18-1.2%$15.00$15.53$15.001,021,412
$15.49+0.09+0.6%$15.41$16.20$15.35792,236
$15.40+0.065+0.4%$15.34$16.31$14.602,078,547
$15.34-0.805-5.0%$15.85$16.08$14.951,130,996
$16.14+0.27+1.7%$16.23$16.34$15.58593,498
$15.87-0.67-4.1%$16.44$16.64$15.60880,375
$16.54+0.14+0.9%$16.40$17.16$15.99678,937
$16.40+0.80+5.1%$15.37$16.56$15.26895,166
$15.60+0.53+3.5%$15.26$16.14$14.78739,448
$15.07+0.97+6.9%$14.16$15.10$13.65595,377
$14.10-0.94-6.2%$15.02$15.03$14.061,286,828
$15.04+0.47+3.2%$15.01$15.19$14.451,136,185
$14.57+0.64+4.6%$14.11$14.85$14.081,448,882
$13.93-0.13-0.9%$14.44$14.44$13.55718,189
$14.06-0.18-1.3%$14.13$14.35$13.83682,307
$14.24-0.35-2.4%$14.71$14.93$14.16896,089
$14.59-0.15-1.0%$14.57$14.90$14.13671,339
$14.74+0.24+1.7%$14.52$15.07$14.36652,895
$14.50-0.09-0.6%$14.69$15.04$14.37477,455
$14.59-0.32-2.1%$14.89$15.00$14.54634,374
$14.91-0.22-1.5%$15.04$15.44$14.36575,900
$15.13+0.27+1.8%$14.84$15.43$14.72932,700
$14.86+1.03+7.4%$13.93$14.96$13.73881,300
$13.83+0.36+2.7%$13.86$14.10$13.54828,500
$13.47-0.29-2.1%$13.78$14.10$13.03981,000
$13.76+0.32+2.4%$13.54$14.18$13.451,038,900
$13.44+0.02+0.1%$13.22$13.66$12.851,172,700
$13.42-0.58-4.1%$14.00$14.24$13.351,329,200
$14.00-0.39-2.7%$14.33$14.45$13.821,355,600
$14.39+0.24+1.7%$14.16$14.81$14.00735,600
$14.15+0.38+2.8%$13.58$14.15$13.181,667,200
$13.77+0.36+2.7%$13.19$14.14$13.08951,300
$13.41-0.66-4.7%$14.20$14.34$13.15493,900
$14.07-0.05-0.4%$14.21$14.71$13.79607,100
$14.12+0.35+2.5%$13.86$14.17$13.311,109,800
$13.77-0.28-2.0%$13.97$14.58$13.591,071,700
$14.05-0.13-0.9%$14.43$14.74$13.95930,900
$14.18-0.17-1.2%$14.35$14.66$13.77627,500
$14.35-0.07-0.5%$14.29$14.71$14.08598,600
$14.42-0.31-2.1%$14.81$15.20$14.39525,800
$14.73+0.02+0.1%$14.59$15.06$14.451,051,300
$14.71-2.05-12.2%$16.64$16.64$14.581,464,700
$16.76+0.02+0.1%$16.92$17.16$16.60643,900
$16.74-0.20-1.2%$17.12$17.67$16.49528,800
$16.94-0.20-1.2%$17.15$17.35$16.792,942,200
$17.14+0.49+2.9%$17.03$17.74$16.94815,700
$16.65-0.73-4.2%$17.52$17.61$16.161,730,500
$17.38-0.80-4.4%$18.16$18.16$17.02849,800
$18.18+0.29+1.6%$18.06$18.83$17.88829,500
$17.89-1.25-6.5%$19.38$20.10$17.531,249,200
$19.14+0.08+0.4%$18.82$19.33$18.591,224,900
$19.06-0.39-2.0%$19.43$19.98$18.791,507,500
$19.45-0.45-2.3%$19.67$20.15$19.00825,600
$19.90+0.05+0.3%$19.86$20.35$19.70605,000
$19.85-1.55-7.2%$21.00$21.27$19.761,381,800
$21.40+0.38+1.8%$21.17$22.00$20.48506,200
$21.02-0.34-1.6%$21.32$21.62$20.73516,600
$21.36+0.52+2.5%$20.65$21.45$20.35837,000
$20.84-0.45-2.1%$21.07$21.40$20.81357,900
$21.29-0.04-0.2%$21.26$21.85$21.13342,600
$21.33-0.51-2.3%$22.40$22.40$21.20355,900
$21.84+0.51+2.4%$21.74$22.16$21.33603,500
$21.33-0.010.0%$21.27$21.78$20.40595,700
$21.34+0.11+0.5%$21.45$22.12$21.13571,800
$21.23-1.32-5.9%$23.82$23.82$20.70936,600
Ticker
BOATS:JBIO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All Jade Biosciences, Inc. news

Jade Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 69 in all · newest Nov 13, 2026 · oldest 2021
Decks
26 decks · latest November 2026

Where Jade Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:JBIO · Home listingNASDAQUnited StatesUSD
BOATS:JBIO · This pageBOATSUnited StatesUSD

Valuation

Price/book 2.3× against a median of 3.8×: 3rd lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$583.6M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.14

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Jade Biosciences, Inc. · NASDAQ:JBIOUS$1.06BUS$583.6Mn/an/an/a2.3×n/a0.0×1.14
Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321US$1.10BUS$1.10B102×6.8×n/a2.9×6.6%0.5×n/a
Pharma Mar SA · BME:PHMUS$1.09BUS$978.3M14.6×3.8×16.6×4.2×28.8%0.3×n/a
Alpha Tau Medical Ltd · NASDAQ:DRTSUS$1.09BUS$1.00Bn/an/an/a55.3×n/a0.8×1.89
Kardigan, Inc. · NASDAQ:KARDUS$1.08BUS$621.1Mn/an/an/a1.9×n/a0.0×n/a
PYC Therapeutics Limited · ASX:PYCUS$1.07BUS$776.2Mn/an/an/a2.3×n/a0.0×n/a
MedinCell SA · EURONEXT:MEDCLUS$1.05BUS$1.02Bn/a38.4×n/a313×−128.9%18.7×n/a
Nektar Therapeutics · NASDAQ:NKTRUS$1.03BUS$492.8Mn/a9.4×n/a1.2×−339.7%0.1×1.28
Mabwell (Shanghai) Bioscience Co., Ltd. Class A · SSE:688062US$1.02BUS$987.0Mn/a9.2×n/a9.5×−146.4%2.9×n/a
SpyGlass Pharma, Inc. · NASDAQ:SGPUS$1.02BUS$809.5Mn/an/an/a4.8×n/a0.0×1.01
Alto Neuroscience, Inc. · NYSE:ANROUS$1.02BUS$711.7Mn/an/an/a3.4×n/a0.1×1.65
Median of the othersUS$1.06BUS$893.9M58.5×9.2×16.6×3.8×−128.9%0.2×1.47

Forecasts

10 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
49.38 USD · Analysts' mean
EPS, year to Dec 2026
-2.93 · 1 analyst

Team and board

Officers

OfficerRole
Lawrence KleinChief Executive Officer, Oruka Therapeutics
Tom FrohlichChief Executive Officer
Brad DahmsChief Financial Officer
Andrew KingPresident, Research & Development
Elizabeth BaltaChief Legal Officer & Corporate Secretary
Amy SullivanSenior Vice President, Development Operations
Jonathan QuickSenior Vice President, Finance
Lori StewartSenior Vice President, People
Sandy LewisSenior Vice President, Biometrics and Clinical Strategy
Valerie FauvelleSenior Vice President, Regulatory & Quality
Chris CainDirector of Research, Fairmount
Edward R. ConnerChief Medical Officer

Board

DirectorRole
Mark EisnerDirector

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · Before open+1.7%
Q2 2026Aug 10, 2026 · Before open−1.1%
Q1 2026May 7, 2026 · After close+6.6%
Q3 2025Nov 12, 2025 · After close−3.2%
Q2 2025Aug 13, 2025 · After close−7.6%
Q1 2025May 14, 2025 · After close−2.0%
Q4 2024Mar 26, 2025
Q3 2024Nov 11, 2024
Q2 2024Aug 12, 2024
Q1 2024May 13, 2024
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 25, 2024
Q3 2023Nov 13, 2023
Q2 2023Aug 14, 2023
Q1 2023May 16, 2023
Q4 2022Mar 29, 2023
Q3 2022Nov 14, 2022
Q2 2022Aug 17, 2022
Q1 2022May 16, 2022
Q4 2021Mar 30, 2022
Quarter to Sep 30, 2021Nov 15, 2021

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck49 slidesNovember 2026
Investor Presentation (October 2026)Investor deck49 slidesOctober 2026
Corporate Update (September 2026)Corporate update18 slidesSep 30, 2026
Investor Presentation (September 2026)Investor deck48 slidesSeptember 2026
Investor Presentation (August 2026)Investor deck45 slidesAugust 2026
Investor Presentation (July 2026)Investor deck38 slidesJuly 2026
Investor Presentation (June 2026)Investor deck39 slidesJune 2026
Technical Presentation (June 2026)Technical22 slidesJun 1, 2026
Investor Presentation (May 2026)Investor deck35 slidesMay 2026
Investor Presentation (March 2026)Investor deck35 slidesMarch 2026
All 26 decks
DeckKindSlidesDate
Investor Presentation (January 2026)Investor deck35 slidesJanuary 2026
Investor Presentation (December 2025)Investor deck35 slidesDecember 2025
Investor Presentation (November 2025)Investor deck35 slidesNovember 2025
JADE201 Conference Call and Webcast (October 2025)Conference15 slidesOct 7, 2025
Investor Presentation (October 2025)Investor deck35 slidesOctober 2025
Investor Presentation (September 2025)Investor deck26 slidesSeptember 2025
Investor Presentation (August 2025)Investor deck25 slidesAugust 2025
Investor Presentation (July 2025)Investor deck28 slidesJuly 2025
ERA 2025 Conference CallConference19 slidesJun 9, 2025
Investor Presentation (June 2025)Investor deck26 slidesJune 2025
Investor Presentation (May 2025)Investor deck25 slidesMay 2025
Investor Presentation (April 2025)Investor deck27 slidesApril 2025
Investor Presentation (April 2025)Investor deck25 slidesApril 2025
Aerovate Therapeutics — Merger or Acquisition (January 2025)Merger or acquisition28 slidesJan 13, 2025
Aerovate Therapeutics — Merger or Acquisition (November 2024)Merger or acquisition29 slidesNov 18, 2024
Investor Presentation (October 2024)Investor deck29 slidesOctober 2024

Open Decks

Financings

RaiseDate
Private placement of shares of common stock
Announced: about US$45M · US$14 a share
Buyers: BB Biotech (3,214,286 shares of common stock for approximately $45 million)
Use of proceeds: Research and development, general corporate expenses, and working capital
Dec 15, 2025
Private placement of common stock and pre-funded warrants
Announced: about US$135M · US$9.14 a share · Jefferies +3
Dealers: Jefferies, TD Cowen, Stifel, Wedbush & Co.
Buyers: Janus Henderson Investors; Fairmount; RA Capital Management; Marshall Wace; Aberdeen Investments; Great Point Partners, LLC; Venrock Healthcare Capital Partners; Samsara BioCapital; Avidity Partners
Use of proceeds: To fund research and development, general corporate expenses, and working capital needs
Oct 7, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Aerovate Therapeutics, Inc. Priced at US$14.00 a share on Jun 29, 2021.

Price
US$14.00 a share
Shares offered
8,682,142 shares of common stock
Offering size
US$121.5 million
Underwriters' option
Up to 1,302,321 more shares
Listing
AVTE on the Nasdaq Global Market
Underwriters
Jefferies, Cowen, Evercore ISI, Wedbush PacGrow · In the order on the cover
Shares delivered
On or about Jul 2, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceMay 6, 2021
Filed publiclyJun 9, 2021
Amended 3 timesNewest Jun 25, 2021
Shares registered with an exchangeJun 25, 2021
Declared effective by the SECJun 29, 2021
Final prospectus, with the priceJun 30, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jun 30, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue0
Cost of revenue26.0K282.0K96.0K68.0K15.0K1.00K
Gross profit-26.0K-282.0K-96.0K-68.0K-15.0K-1.00K
Research and development93.1M53.2M64.2M38.6M15.0M7.94M
Selling, general and administrative20.2M8.61K
Operating income-113.5M-74.6M-81.4M-53.2M-23.0M-8.89M
Depreciation and amortization26.0K282.0K96.0K68.0K15.0K1.00K
EBITDA-113.5M-74.3M-81.3M-53.2M-23.0M-8.89M
Interest expense75.0K
Income before tax-127.4M-69.6M-75.5M-51.5M-23.0M-9.61M
Income tax58.0K55.0K56.0K25.0K3.00K
Net income-127.4M-69.6M-75.5M-51.5M-23.0M-9.61M
Earnings per share, basic-3.19-2.44-2.87-2.10-1.87-40.31
Earnings per share, diluted-3.19-2.44-2.87-2.10-1.87-40.31

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents88.4M69.4M23.5M22.4M54.2M4.57M
Short-term investments247.7M098.9M106.8M113.2M
Current assets348.8M69.7M124.2M131.5M174.3M4.68M
Property, plant and equipment170.0K0288.0K242.0K186.0K39.0K
Total assets349.8M72.8M127.4M135.3M175.4M4.71M
Accounts payable2.15M1.29M2.40M2.58M1.21M618.0K
Current liabilities16.5M12.0M17.6M7.78M2.55M1.77M
Long-term debt107.6M
Total debt724.0K417.0K675.0K1.09M574.0K
Total liabilities17.3M119.6M18.0M8.56M2.94M1.77M
Shareholders' equity332.5M-46.8M109.5M126.7M172.4M-13.3M
Shares outstanding49.3M3.67M27.8M24.7M24.4M243.1K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-94.7M-71.2M-56.8M-39.1M-27.4M-7.86M
Capital spending-196.0K0-142.0K-195.0K-181.0K0
Free cash flow-94.9M-71.2M-56.9M-39.3M-27.6M-7.86M
Cash from investing-247.0M56.0M11.9M6.93M-113.4M
Cash from financing360.8M25.4M46.0M396.0K190.5M8.92M
Change in cash19.1M10.3M1.09M-31.8M49.6M1.06M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 13, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 28, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
8-K · Current reportSep 30, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
8-K · Current reportAug 10, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 8, 2026Big-stake noticeSEC
8-K · Current reportJul 1, 2026Material contractSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 26, 2026Insider tradeSEC
8-K · Current reportJun 26, 2026Management or board changeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Meeting outcomeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 9, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialJun 5, 2026Meeting noticeSEC
8-K · Current reportJun 4, 2026Current reportSEC
424B5 · ProspectusJun 4, 2026Offer documentSEC
424B5 · ProspectusJun 3, 2026Offer documentSEC
8-K · Current reportJun 1, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMay 18, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveMay 18, 2026Other filingsSEC
424B3 · ProspectusMay 15, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
CORRESP · Letter to the SECMay 13, 2026Other filingsSEC
CORRESP · Letter to the SECMay 13, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 13, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 13, 2026Other filingsSEC
S-8 · Registration statement for employee plansMay 7, 2026Offer documentSEC
S-3 · Registration statementMay 7, 2026Offer documentSEC
S-3 · Registration statementMay 7, 2026Offer documentSEC
424B3 · ProspectusMay 7, 2026Offer documentSEC
424B3 · ProspectusMay 7, 2026Offer documentSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 27, 2026Big-stake noticeSEC
8-K · Current reportApr 22, 2026Management or board changeSEC
PRE 14A · Preliminary proxy statementApr 17, 2026Meeting noticeSEC
8-K · Current reportApr 2, 2026Management or board changeSEC
S-8 · Registration statement for employee plansMar 6, 2026Offer documentSEC
POS EXMar 6, 2026Other filingsSEC
POS EXMar 6, 2026Other filingsSEC
424B3 · ProspectusMar 6, 2026Offer documentSEC
424B3 · ProspectusMar 6, 2026Offer documentSEC
10-K · Annual reportMar 6, 2026Annual reportSEC
8-K · Current reportMar 6, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 5, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
8-K · Current reportJan 5, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveDec 31, 2025Other filingsSEC
424B3 · ProspectusDec 30, 2025Offer documentSEC
CORRESP · Letter to the SECDec 23, 2025Other filingsSEC
UPLOAD · Letter from the SECDec 23, 2025Other filingsSEC
S-1 · Registration statementDec 22, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 22, 2025Other filingsSEC
424B3 · ProspectusDec 19, 2025Offer documentSEC
CORRESP · Letter to the SECDec 17, 2025Other filingsSEC
8-K · Current reportDec 15, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
S-1 · Registration statementNov 14, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 14, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 17, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 16, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 8, 2025Big-stake noticeSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
8-K · Current reportOct 7, 2025Material contractSEC
8-K · Current reportSep 9, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedAug 13, 2025Other filingsSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJul 14, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 14, 2025Insider tradeSEC
8-K · Current reportJul 1, 2025Material contractSEC
S-8 · Registration statement for employee plansJun 30, 2025Offer documentSEC
144 · Notice of proposed saleJun 25, 2025Other filingsSEC
144 · Notice of proposed saleJun 25, 2025Other filingsSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeJun 20, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 6, 2025Big-stake noticeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 14, 2025ResultsSEC
144 · Notice of proposed saleMay 6, 2025Other filingsSEC
144 · Notice of proposed saleMay 6, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 5, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 5, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeMay 1, 2025Big-stake noticeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2025Insider tradeSEC
8-K · Current reportMay 1, 2025ResultsSEC
4 · Change in ownershipApr 30, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 30, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 30, 2025Big-stake noticeSEC
8-K · Current reportApr 29, 2025Current reportSEC
10-Q · Quarterly reportApr 25, 2025Quarterly reportSEC
8-K · Current reportApr 23, 2025Current reportSEC
8-K · Current reportApr 21, 2025Meeting outcomeSEC
425Apr 9, 2025Other filingsSEC
425Apr 9, 2025Other filingsSEC
8-K · Current reportApr 9, 2025Current reportSEC
425Apr 9, 2025Other filingsSEC
8-K · Current reportApr 9, 2025Current reportSEC
425Apr 7, 2025Other filingsSEC
425Apr 7, 2025Other filingsSEC
8-K · Current reportApr 7, 2025Current reportSEC
SEC STAFF LETTERMar 27, 2025Other filingsSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
425Mar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
ARS · Annual report to shareholdersMar 25, 2025Annual reportSEC
424B3 · ProspectusMar 25, 2025Offer documentSEC
CORRESP · Letter to the SECMar 24, 2025Other filingsSEC
CORRESP · Letter to the SECMar 24, 2025Other filingsSEC
CORRESP · Letter to the SECMar 24, 2025Other filingsSEC
S-4/A · Registration statement, amendedMar 24, 2025Offer documentSEC
UPLOAD · Letter from the SECMar 21, 2025Other filingsSEC
CORRESP · Letter to the SECMar 14, 2025Other filingsSEC
S-4/A · Registration statement, amendedMar 14, 2025Offer documentSEC
UPLOAD · Letter from the SECMar 11, 2025Other filingsSEC
425Mar 3, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 24, 2025Other filingsSEC
S-4/A · Registration statement, amendedFeb 24, 2025Offer documentSEC
SEC STAFF LETTERFeb 19, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 18, 2025Other filingsSEC
425Feb 10, 2025Other filingsSEC
425Feb 4, 2025Other filingsSEC
425Jan 24, 2025Other filingsSEC
S-4/A · Registration statement, amendedJan 22, 2025Offer documentSEC
425Jan 13, 2025Other filingsSEC
S-4 · Registration statementDec 3, 2024Offer documentSEC
RW · Request to withdraw a registrationNov 25, 2024Other filingsSEC
425Nov 18, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
425Oct 31, 2024Other filingsSEC
425Oct 31, 2024Other filingsSEC
425Oct 31, 2024Other filingsSEC
425Oct 31, 2024Other filingsSEC
425Oct 31, 2024Other filingsSEC
8-K · Current reportOct 31, 2024Material contractSEC
8-K · Current reportOct 17, 2024Current reportSEC
8-K · Current reportOct 10, 2024Management or board changeSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
4 · Change in ownershipAug 2, 2024Insider tradeSEC
8-K · Current reportJul 8, 2024Current reportSEC
8-K/A · Current report, amendedJul 1, 2024Current reportSEC
8-K · Current reportJun 28, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedJun 20, 2024Big-stake noticeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
8-K · Current reportJun 17, 2024Current reportSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
144 · Notice of proposed saleJun 14, 2024Other filingsSEC
144 · Notice of proposed saleJun 13, 2024Other filingsSEC
S-3 · Registration statementJun 10, 2024Offer documentSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC

This page holds 200 of 515 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Jade Biosciences, Inc.’s releases · as of Nov 6, 2026

Common shares
69,189,448
Fully diluted
69,189,448

Fully diluted

LineSharesAs of
Common shares69,189,448Nov 6, 2026

Share count over time

CountShares
Nov 6, 202669,189,448

Open Cap table

Shareholders

Institutions

HolderSharesValueChange vs Jun 30Filed
Fidelity9.81MUS$138M+683KNov 10, 2026
Janus Henderson6.99MUS$98.1MFirst reportNov 16, 2026
Paradigm Biocapital Advisors LP6.05MUS$85M+3.2MNov 16, 2026
Fairmount Funds Management LLC4.55MUS$64MNo changeNov 16, 2026
Bellevue Group AG4.29MUS$60.3M+1.24MNov 16, 2026
Franklin Templeton3.81MUS$57.3M+1.02MNov 12, 2026
BlackRock3.37MUS$47.3M+565KNov 13, 2026
Vanguard3.3MUS$46.4M+211KNov 13, 2026
Venrock Adviser, LLC3.22MUS$45.2MNo changeNov 16, 2026
State Street2.6MUS$36.6M+268KNov 12, 2026
Show 50 holders
HolderSharesValueChange vs Jun 30Filed
Avidity Partners Management LP2MUS$28.1M+299KNov 16, 2026
Polar Capital Holdings Plc1.84MUS$25.9M−3,265Nov 16, 2026
Ra Capital Management, L.P.1.84MUS$25.8M−1.84MNov 16, 2026
Remedium Capital Partners, LLC1.81MUS$25.4M+230KNov 13, 2026
JPMorgan1.47MUS$20.8M−5,935Nov 12, 2026
T. Rowe Price1.4MUS$19.6M+1.37MNov 16, 2026
Baker Bros. Advisors LP1.23MUS$17.3MNo changeNov 16, 2026
Pictet Asset Management Holding SA1.21MUS$16.9M+472KNov 3, 2026
Geode Capital1.2MUS$16.9M+217KNov 6, 2026
Soleus Capital Management, L.P.1.17MUS$16.5M−380KNov 16, 2026
Versant Venture Management, LLC992KUS$13.9MNo changeNov 13, 2026
Acorn Capital Advisors, LLC987KUS$13.9MNo changeNov 16, 2026
Adage Capital Partners Gp, L.L.C.950KUS$13.3M−961KNov 16, 2026
Citadel929KUS$13.1M−116Nov 16, 2026
Goldman Sachs897KUS$12.6M+162KNov 16, 2026
Foresite Capital Management VI LLC887KUS$12.5MNo changeNov 16, 2026
Affinity Asset Advisors, LLC760KUS$10.7M−80,000Nov 13, 2026
Samsara Biocapital, LLC736KUS$10.3MNo changeNov 16, 2026
Blackstone Inc.677KUS$9.51M+241KNov 16, 2026
Lord, Abbett & Co. LLC667KUS$9.37M+440KNov 13, 2026
abrdn551KUS$7.74M−70,221Nov 10, 2026
BNP Paribas529KUS$7.43M+329KNov 12, 2026
Stempoint Capital LP472KUS$6.63MNewNov 16, 2026
Marshall Wace, LLP459KUS$6.45M−127KNov 13, 2026
Schwab444KUS$6.24M+344KNov 16, 2026
Ikarian Capital, LLC427KUS$6MNo changeNov 16, 2026
Millennium421KUS$5.91M+106KNov 16, 2026
Point72 Asset Management, L.P.382KUS$5.37M+215KNov 16, 2026
Northern Trust381KUS$5.36M+86,236Nov 16, 2026
Connor, Clark & Lunn Investment Management Ltd.342KUS$4.81M+125KNov 10, 2026
Jump Financial, LLC303KUS$4.25M+130KNov 13, 2026
Cormorant Asset Management, LP300KUS$4.21MNewNov 16, 2026
UBS263KUS$3.69M+113KNov 16, 2026
Schroders262KUS$3.72M+121KNov 16, 2026
XTX Topco Ltd219KUS$3.08M+160KNov 16, 2026
Logos Global Management LP200KUS$2.81M−925KNov 19, 2026
Bank of America190KUS$2.67M−297KNov 16, 2026
Walleye Capital LLC180KUS$2.54M−185KNov 13, 2026
Russell Investments Group, Ltd.179KUS$2.52M+16,348Nov 6, 2026
TD174KUS$2.47MNewNov 13, 2026

This page holds 50 of 156 holders. Open Shareholders

Funds

HolderSharesValueChangeAs of
Vanguard Total Stock Market Index Fund1.7MUS$37.8M+314KJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.53MUS$34.1MNewJun 30, 2026
Franklin Small Cap Value Fund1.41MUS$27.9MNewJul 31, 2026
Fidelity Growth Company Fund1.01MUS$21.2MNo changeMay 31, 2026
Fidelity Stock Selector Small Cap Fund908KUS$17.9M+214KJul 31, 2026
iShares Russell 2000 ETF852KUS$18.9M+52,980Jun 30, 2026
Fidelity Small Cap Growth Fund780KUS$15.4M+264KJul 31, 2026
Janus Henderson Global Life Sciences Fund717KUS$15.9MNewJun 30, 2026
Fidelity Advisor Biotechnology Fund699KUS$13.8M−196KJul 31, 2026
JPMorgan Small Cap Growth Fund678KUS$15.1MNewJun 30, 2026
Show 50 holders
HolderSharesValueChangeAs of
Select Health Care Portfolio640KUS$13.5M+240KMay 31, 2026
Fidelity Series Small Cap Opportunities Fund589KUS$11.6M+93,400Jul 31, 2026
Vanguard Extended Market Index Fund485KUS$10.8M+118KJun 30, 2026
Franklin Biotechnology Discovery Fund480KUS$9.48M+342KJul 31, 2026
Franklin Small Cap Growth Fund433KUS$8.55MNewJul 31, 2026
Fidelity Small Cap Growth K6 Fund376KUS$7.43M+145KJul 31, 2026
Fidelity Advisor Health Care Fund371KUS$7.32M+90,600Jul 31, 2026
Fidelity Small Cap Index Fund357KUS$7.05M+23,833Jul 31, 2026
Select Biotechnology Portfolio322KUS$6.77MNo changeMay 31, 2026
Fidelity Growth Company K6 Fund300KUS$6.31M−3,912May 31, 2026
iShares Russell 2000 Growth ETF299KUS$6.64MNewJun 30, 2026
Fidelity Series Growth Company Fund261KUS$5.5M−6,900May 31, 2026
JPMorgan Small Cap Blend Fund217KUS$4.83MNewJun 30, 2026
Fidelity Extended Market Index Fund168KUS$3.54M+54,297May 31, 2026
Vanguard Russell 2000 Index Fund164KUS$3.44M−65,954May 31, 2026
VIP Health Care Portfolio154KUS$3.41M+93,646Jun 30, 2026
Franklin Small Cap Value VIP Fund152KUS$3.37MNewJun 30, 2026
Lord Abbett Micro-Cap Growth Fund126KUS$2.48MNewJul 31, 2026
iShares Micro-Cap ETF109KUS$2.43M+29,298Jun 30, 2026
SA Franklin Small Company Value Portfolio99,410US$1.96MNewJul 31, 2026
Fidelity Fundamental Small-Mid Cap ETF93,021US$1.84M+2,841Jul 31, 2026
Vanguard U.S. Momentum Factor ETF90,592US$1.91M+71,205May 31, 2026
Schwab Small-Cap Index Fund79,164US$1.56M+9,149Jul 31, 2026
Franklin Mutual Small-Mid Cap Value Fund77,082US$1.52MNewJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF70,615US$1.57MNewJun 30, 2026
Master Small Cap Index Series60,859US$1.35M+9,062Jun 30, 2026
Fidelity Total Market Index Fund60,757US$1.28M+18,879May 31, 2026
Fidelity Small Cap Discovery Fund57,800US$1.14MNewJul 31, 2026
Avantis U.S. Small Cap Equity ETF53,058US$1.12M+27,816May 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares52,113US$1.03MNewJul 31, 2026
Fidelity Series Small Cap Discovery Fund51,300US$1.01MNewJul 31, 2026
Fidelity Series Total Market Index Fund49,607US$1.04M+17,638May 31, 2026
Nuveen Small Cap Blend Index Fund43,159US$852K+4,603Jul 31, 2026
1290 VT Micro Cap Portfolio38,432US$854K+32,678Jun 30, 2026
Tax-Managed U.S. Mid & Small Cap Fund37,540US$741KNo changeJul 31, 2026
EQ/2000 Managed Volatility Portfolio35,575US$790K+1,860Jun 30, 2026
U.S. Small Cap Equity Fund32,518US$642K+6,468Jul 31, 2026
Fidelity Small Cap Growth Index Fund30,506US$678KNewJun 30, 2026
Fidelity Nasdaq Composite Index Fund30,019US$632K+1,423May 31, 2026
Vanguard Balanced Index Fund29,049US$645K+5,217Jun 30, 2026

This page holds 50 of 141 holders. Open Shareholders

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Peter Kolchinsky
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Wave Life Sciences Ltd. (Director · Since at least Aug 14, 2015); Black Diamond Therapeutics, Inc. (Director · Jul 5, 2023 – Jul 5, 2023 · Past); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Research Alliance Corp II (Chief Executive Officer, Director · Mar 17, 2021 – Mar 17, 2021 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Solid Biosciences Inc. (Director · Dec 10, 2020 – Jan 11, 2024 · Past); POINT Biopharma Global Inc (Chief Executive Officer, Director · Jul 7, 2020 – Jun 29, 2021 · Past); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Jun 8, 2022 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 3, 2022 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Kala Bio, Inc. (Director · Oct 3, 2018 – Mar 13, 2020 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – Jun 19, 2018 · Past); KalVista Pharmaceuticals, Inc. (Director · Oct 12, 2017 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Jun 20, 2017 – Apr 2, 2020 · Past); Dicerna Pharmaceuticals Inc (Director · Jan 29, 2014 – Nov 27, 2019 · Past)
Director · Jun 29, 2021 – Jun 17, 2024 · Past
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Jun 29, 2021 – Jun 17, 2024 · Past
Peter Harwin
Other companies: Alaunos Therapeutics, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Oct 13, 2026); Damora Therapeutics, Inc. (Chairman of the Board · Since at least Nov 10, 2025); Crescent Biopharma, Inc. (Chair of Board · Since at least Jun 13, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Cogent Biosciences, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Jul 6, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Jan 22, 2024 · Past); Viridian Therapeutics, Inc. (Director · Oct 27, 2020 – Jun 26, 2024 · Past)
Director · Since at least Apr 28, 2025
Habib Joseph Dable
Other companies: Tyra Biosciences, Inc. (Board Member · Since at least Apr 16, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Relay Therapeutics, Inc. (Director · Since at least Nov 4, 2025); Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); PepGen Inc. (Non-Executive Director · Since at least Sep 20, 2022); Blueprint Medicines Corp (Director · Since at least Jun 23, 2022); Albireo Pharma Inc (Director · Aug 8, 2022 – Mar 2, 2023 · Past); Tempest Therapeutics, Inc. (Director · Dec 7, 2018 – Jun 22, 2020 · Past); Acceleron Pharma Inc (CEO and President, Director · Dec 1, 2016 – Nov 19, 2021 · Past)
Director · Jul 10, 2023 – Jun 5, 2024 · Past
Tomas Kiselak
Other companies: Cyclerion Therapeutics, Inc. (Chairman · Since at least Apr 1, 2026); Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Viridian Therapeutics, Inc. (Director · Since at least Oct 27, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Sep 27, 2024 · Past)
Director · Since at least Apr 28, 2025
Mark Iwicki
Other companies: Inhibikase Therapeutics, Inc. (Chief Executive Officer - Inhibikase · Since at least Feb 14, 2025); Q32 Bio Inc. (Director · Since at least Mar 25, 2024); Third Harmonic Bio Inc. (Director · Since at least Sep 14, 2022); Akero Therapeutics Inc (Director · Since at least Jun 19, 2019); Kala Bio, Inc. (Director · Since at least Jul 19, 2017); Pulmatrix, Inc. (Director · Mar 20, 2017 – Jan 28, 2021 · Past); Aimmune Therapeutics Inc (Director · May 25, 2016 – Oct 10, 2020 · Past)
Director · Apr 2, 2021 – Jun 5, 2024 · Past
Joshua Resnick
Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Cidara Therapeutics Inc (Director · Since at least Jan 3, 2025); PepGen Inc. (Director · Since at least May 5, 2022); Vor Biopharma Inc. (Director · Feb 4, 2021 – May 22, 2025 · Past); Tectonic Therapeutic, Inc. (Director · Jun 20, 2018 – Jun 20, 2018 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Sep 27, 2017 · Past)
Director · Jun 29, 2021 – Jun 5, 2024 · Past
Edward R. Conner
Other companies: Ardelyx, Inc. (Chief Medical Officer · Since at least Aug 1, 2025); Third Harmonic Bio Inc. (Chief Medical Officer · Sep 14, 2022 – Jan 15, 2025 · Past); Enliven Therapeutics, Inc. (Director · Apr 22, 2020 – Jun 2, 2022 · Past); Audentes Therapeutics Inc (SVP, Chief Medical Officer · Jul 15, 2019 – Jan 15, 2020 · Past); Sangamo Therapeutics, Inc. (Sr. VP & Chief Medical Officer · Nov 30, 2016 – Jan 24, 2019 · Past)
Chief Medical Officer · Since Apr 22, 2026
Eric Dobmeier
Other companies: Janux Therapeutics, Inc. (Director · Since at least Jul 19, 2024); Structure Therapeutics, Inc. (Director · Since at least Feb 2, 2023); Aduro Biotech Inc (President, CEO, Director · Oct 5, 2020 – Aug 11, 2023 · Past); Atara Biotherapeutics, Inc. (Director · Jun 27, 2019 – Nov 10, 2023 · Past); Adaptive Biotechnologies Corporation (Director · Jun 26, 2019 – Feb 14, 2021 · Past)
Director · Since at least Apr 28, 2025
Allison Dorval
Other companies: Verve Therapeutics Inc (Chief Financial Officer · Since at least Nov 29, 2021); Puma Biotechnology Inc (Director · Since at least Jul 15, 2021); Voyager Therapeutics, Inc. (Chief Financial Officer · Jun 8, 2018 – Mar 19, 2021 · Past); Insulet Corporation (Chief Financial Officer · Nov 6, 2014 – Apr 1, 2015 · Past)
Director · Jul 15, 2021 – Jun 5, 2024 · Past
All 38 people
PersonSeat
Donald J Santel
Other companies: Oyster Point Pharma Inc (Director · Jul 30, 2021 – Jan 3, 2023 · Past); Surrozen, Inc. (Director · Nov 18, 2020 – Nov 18, 2020 · Past); Hyperion Therapeutics Inc (CEO & President, Director · Jul 25, 2012 – May 7, 2015 · Past); Anthera Pharmaceuticals Inc (Director · Feb 23, 2010 – Jun 30, 2011 · Past)
Director · Jan 19, 2023 – Jun 5, 2024 · Past
Erin Lavelle
Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); Neurogene Inc. (Director · May 12, 2022 – Jun 8, 2023 · Past); Climb Bio, Inc. (COO & CFO · Aug 9, 2021 – Oct 31, 2022 · Past); Alder BioPharmaceuticals Inc (Chief Operating Officer · Apr 16, 2018 – Oct 22, 2019 · Past)
Director · Since at least Apr 28, 2025
Lawrence Klein
Other companies: Oruka Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Aug 29, 2024); Jasper Therapeutics, Inc. (Director · Sep 24, 2021 – Jun 7, 2023 · Past); Dyne Therapeutics, Inc. (Director · Jul 31, 2020 – Jul 5, 2022 · Past); CRISPR Therapeutics AG (CBO & COO · Jan 2, 2019 – Aug 16, 2022 · Past)
Chief Executive Officer, Oruka Therapeutics · Since at least Apr 28, 2025
Chris Cain
Other companies: Damora Therapeutics, Inc. (Board Director · Since at least Nov 10, 2025); Viridian Therapeutics, Inc. (Director · Since at least Mar 10, 2025); Cogent Biosciences, Inc. (Director · Since at least Jul 6, 2020)
Director · Since at least Apr 28, 2025
Mark Eisner
Other companies: Zura Bio Limited (Director · Since at least Feb 21, 2026); Vir Biotechnology, Inc. (EVP and Chief Medical Officer · Since at least Jun 3, 2024); Kyntra Bio, Inc. (EVP, Chief Medical Officer · Dec 1, 2020 – Sep 6, 2023 · Past)
Director · Since at least Jun 25, 2026
Bradford D Dahms
Other companies: Theseus Pharmaceuticals Inc (President and CFO · Oct 6, 2021 – Feb 14, 2024 · Past); Cartesian Therapeutics, Inc. (Chief Financial Officer · Sep 3, 2019 – Jan 4, 2021 · Past)
Chief Financial Officer · Since at least Jul 14, 2025
David Grayzel
Other companies: Q32 Bio Inc. (Director · Since at least Mar 25, 2024); Surface Oncology Inc (Director · Apr 18, 2018 – Sep 8, 2023 · Past)
Director · Feb 1, 2021 – Jun 5, 2024 · Past
George A Eldridge
Other companies: Protara Therapeutics, Inc. (Sr VP, CFO, Treasr, Asst Secy · Oct 21, 2014 – Jan 18, 2019 · Past); Targanta Therapeutics Corp (CFO,Treasurer & Asst Secretary · Oct 10, 2007 – Feb 6, 2008 · Past)
SEE REMARKS · Apr 2, 2021 – Jun 14, 2024 · Past
Maha Katabi
Other companies: RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Vera Therapeutics, Inc. (Director · May 13, 2021 – May 14, 2025 · Past)
Director · Feb 1, 2021 – Jun 5, 2024 · Past
Andrew King
Other companies: Aduro Biotech Inc (Chief Scientific Officer · Oct 5, 2020 – Aug 11, 2023 · Past)
President, Research & Development · Since at least Apr 28, 2025
Chris Cain
Other companies: Cogent Biosciences, Inc. (Member of the Compensation Committee, Chair of the Science & Technology Committee · Since at least Nov 4, 2026)
Director of Research, Fairmount · Since at least Nov 4, 2026
Elizabeth Bekiroglu
Other companies: Icosavax Inc (General Counsel & Corp. Sec. · Sep 21, 2021 – Feb 15, 2023 · Past)
See Remarks · Since at least Apr 28, 2025
Jonathan Quick
Other companies: LogicBio Therapeutics Inc (Senior Director-Finance · Jan 1, 2021 – Jan 1, 2021 · Past)
Senior Vice President, Finance · Since at least Apr 28, 2025
Timothy Pigot
Other companies: Inhibikase Therapeutics, Inc. (Chief Commercial and Strategy Officer · Since at least Aug 19, 2025)
CHIEF COMMERCIAL OFFICER · Mar 7, 2023 – Jan 22, 2024 · Past
Timothy P Noyes
Other companies: Protara Therapeutics, Inc. (President and CEO, Director · Oct 21, 2014 – Jan 31, 2019 · Past)
CHIEF EXECUTIVE OFFICER, Director · Apr 2, 2021 – May 16, 2024 · Past
Tom Frohlich
Other companies: Aduro Biotech Inc (Chief Operating Officer · Oct 5, 2020 – Aug 11, 2023 · Past)
Chief Executive Officer, Director · Since at least Apr 28, 2025
Amy SullivanSenior Vice President, Development Operations · Since at least Nov 5, 2026
Benjamin T DakeSEE REMARKS · Apr 2, 2021 – Jul 31, 2024 · Past
Brad DahmsChief Financial Officer · Since at least Jul 1, 2025
Elizabeth BaltaChief Legal Officer & Corporate Secretary · Since at least Nov 5, 2026
Hetal KocinskyChief Medical Officer · Apr 28, 2025 – Apr 28, 2025 · Past
Hunter GilliesCHIEF MEDICAL OFFICER · Apr 2, 2021 – Jun 13, 2024 · Past
Lori StewartSenior Vice President, People · Since at least Nov 5, 2026
Marinus VerwijsCHIEF TECHNICAL OFFICER · Mar 21, 2022 – Jun 14, 2024 · Past
Ralph NivenCHIEF SCIENTIFIC OFFICER · Apr 2, 2021 – Feb 5, 2024 · Past
Sandy LewisSenior Vice President, Biometrics and Clinical Strategy · Since at least Nov 4, 2026
Tom FrohlichChief Executive Officer · Since at least Aug 10, 2026
Valerie FauvelleSenior Vice President, Regulatory & Quality · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Jade Biosciences, Inc.